ES2580135T3 - Métodos de tratamiento de carcinoma hepatocelular - Google Patents
Métodos de tratamiento de carcinoma hepatocelular Download PDFInfo
- Publication number
- ES2580135T3 ES2580135T3 ES11760333.2T ES11760333T ES2580135T3 ES 2580135 T3 ES2580135 T3 ES 2580135T3 ES 11760333 T ES11760333 T ES 11760333T ES 2580135 T3 ES2580135 T3 ES 2580135T3
- Authority
- ES
- Spain
- Prior art keywords
- composition
- nanoparticles
- albumin
- taxane
- paclitaxel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31815310P | 2010-03-26 | 2010-03-26 | |
| US318153P | 2010-03-26 | ||
| PCT/US2011/030037 WO2011119988A1 (en) | 2010-03-26 | 2011-03-25 | Methods of treatment of hepatocellular carcinoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2580135T3 true ES2580135T3 (es) | 2016-08-19 |
Family
ID=44673662
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11760333.2T Active ES2580135T3 (es) | 2010-03-26 | 2011-03-25 | Métodos de tratamiento de carcinoma hepatocelular |
| ES14200645.1T Active ES2675212T3 (es) | 2010-03-26 | 2011-03-25 | Métodos de tratamiento de carcinoma hepatocelular |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14200645.1T Active ES2675212T3 (es) | 2010-03-26 | 2011-03-25 | Métodos de tratamiento de carcinoma hepatocelular |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9370494B2 (enExample) |
| EP (2) | EP2898884B1 (enExample) |
| JP (2) | JP5847156B2 (enExample) |
| KR (1) | KR101786142B1 (enExample) |
| CN (2) | CN103052385B (enExample) |
| AU (1) | AU2011230512B2 (enExample) |
| BR (1) | BR112012024349A2 (enExample) |
| CA (2) | CA2793536C (enExample) |
| DK (1) | DK2552438T3 (enExample) |
| ES (2) | ES2580135T3 (enExample) |
| HR (1) | HRP20160609T1 (enExample) |
| HU (1) | HUE027749T2 (enExample) |
| IL (2) | IL221886A (enExample) |
| LT (1) | LT2552438T (enExample) |
| MX (2) | MX359413B (enExample) |
| NZ (1) | NZ602382A (enExample) |
| PL (1) | PL2552438T3 (enExample) |
| PT (1) | PT2552438T (enExample) |
| TW (1) | TWI495467B (enExample) |
| WO (1) | WO2011119988A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| EP1585548B1 (en) | 2002-12-09 | 2018-06-27 | Abraxis BioScience, LLC | Compositions and methods of delivery of pharmacological agents |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| ES2678448T3 (es) | 2005-02-18 | 2018-08-10 | Abraxis Bioscience, Llc | Combinaciones y modos de administración de agentes terapéuticos y terapia combinada |
| TWI417114B (zh) | 2005-08-31 | 2013-12-01 | Abraxis Bioscience Llc | 具有增強穩定性之弱水溶性藥物之組合物及其製備方法 |
| CA2672618C (en) | 2006-12-14 | 2021-03-02 | Abraxis Bioscience, Llc | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| KR20090118999A (ko) * | 2007-03-07 | 2009-11-18 | 아브락시스 바이오사이언스, 엘엘씨 | 항암제로서 라파마이신 및 알부민을 포함하는 나노입자 |
| DK2155188T3 (da) * | 2007-06-01 | 2013-11-04 | Abraxis Bioscience Llc | Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft |
| CN102460167B (zh) | 2009-04-15 | 2015-07-22 | 阿布拉科斯生物科学有限公司 | 不含朊病毒的纳米颗粒组合物和方法 |
| ES2580135T3 (es) | 2010-03-26 | 2016-08-19 | Abraxis Bioscience, Llc | Métodos de tratamiento de carcinoma hepatocelular |
| AU2011232862B2 (en) | 2010-03-29 | 2016-03-03 | Abraxis Bioscience, Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
| NZ628423A (en) | 2010-03-29 | 2016-03-31 | Abraxis Bioscience Llc | Methods of treating cancer |
| RU2576609C2 (ru) | 2010-06-04 | 2016-03-10 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечение рака поджелудочной железы |
| CA3063641A1 (en) | 2011-04-28 | 2012-11-01 | Abraxis Bioscience, Llc | Intravascular delivery of nanoparticle compositions and uses thereof |
| DK2790675T3 (da) | 2011-12-14 | 2019-09-09 | Abraxis Bioscience Llc | Anvendelse af polymerexcipienser til frysetørring eller frysning af partikler |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US20140186447A1 (en) * | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| NZ630392A (en) | 2013-03-12 | 2016-10-28 | Abraxis Bioscience Llc | Methods of treating lung cancer |
| RU2015143490A (ru) | 2013-03-14 | 2017-04-26 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечения рака мочевого пузыря |
| WO2014191569A1 (en) | 2013-05-30 | 2014-12-04 | Nanobiotix | Pharmaceutical composition, preparation and uses thereof |
| US20150247204A1 (en) * | 2014-02-07 | 2015-09-03 | The General Hopital Corporation | Differential diagnosis of hepatic neoplasms |
| TW201628644A (zh) * | 2014-11-25 | 2016-08-16 | 奈諾生技公司 | 醫藥組合物、其製備及其用途 |
| PT3229776T (pt) | 2014-11-25 | 2023-08-17 | Curadigm Sas | Composição farmacêutica combinando pelo menos duas nanopartícuas distintas e um composto farmacêutico, preparaçâo e suas utilizações |
| AR102780A1 (es) | 2014-11-25 | 2017-03-22 | Nanobiotix | Composiciones farmacéuticas, su preparación y sus usos |
| US10765632B2 (en) | 2014-11-25 | 2020-09-08 | Curadigm Sas | Methods of improving delivery of compounds for therapy, prophylaxis or diagnosis |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| MA43100A (fr) | 2015-05-28 | 2018-09-05 | Nanobiotix | Nanoparticules à utiliser en tant que vaccin thérapeutique |
| HUE070408T2 (hu) | 2015-06-29 | 2025-06-28 | Abraxis Bioscience Llc | Szirolimuszt és albumint tartalmazó nanorészecskék epitelioid sejtes tumorok kezelésében történõ alkalmazásra |
| BR112019006329A2 (pt) * | 2016-10-07 | 2019-06-25 | Abraxis Bioscience Llc | métodos de tratamento de câncer do trato biliar |
| US11419842B2 (en) * | 2016-10-27 | 2022-08-23 | Zhuhai Beihai Biotech Co., Ltd. | Neutral pH compositions of Docetaxel and human serum albumin |
| US10896749B2 (en) * | 2017-01-27 | 2021-01-19 | Shire Human Genetic Therapies, Inc. | Drug monitoring tool |
| CN107828887A (zh) * | 2017-10-12 | 2018-03-23 | 上海市东方医院 | Stmn1基因的用途 |
| WO2019183146A1 (en) | 2018-03-20 | 2019-09-26 | Abraxis Bioscience, Llc | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
| JP2022553426A (ja) | 2019-10-28 | 2022-12-22 | アブラクシス バイオサイエンス， エルエルシー | アルブミンおよびラパマイシンの医薬組成物 |
| JP2024542042A (ja) * | 2021-10-26 | 2024-11-13 | リポジェムス・インターナショナル・エッセ・ピ・ア | 肝がん療法での薬物送達システムとしての微小断片化脂肪組織 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5997904A (en) | 1993-02-22 | 1999-12-07 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US20030068362A1 (en) | 1993-02-22 | 2003-04-10 | American Bioscience, Inc. | Methods and formulations for the delivery of pharmacologically active agents |
| US6528067B1 (en) | 1993-02-22 | 2003-03-04 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
| US5650156A (en) | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
| US5362478A (en) | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
| US5665383A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of immunostimulating agents for in vivo delivery |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US5665382A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of pharmaceutically active agents for in vivo delivery |
| WO1994018954A1 (en) | 1993-02-22 | 1994-09-01 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of biologics and compositions useful therefor |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US6565842B1 (en) | 1995-06-07 | 2003-05-20 | American Bioscience, Inc. | Crosslinkable polypeptide compositions |
| US8137684B2 (en) | 1996-10-01 | 2012-03-20 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20030199425A1 (en) | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| PT1023050E (pt) | 1997-06-27 | 2013-12-04 | Abraxis Bioscience Llc | Novas formulações de agentes farmacológicos, métodos para a sua preparação e métodos para a sua utilização |
| AU777528B2 (en) | 1999-04-22 | 2004-10-21 | Abraxis Bioscience, Llc | Long term administration of pharmacologically active agents |
| WO2000071079A2 (en) | 1999-05-21 | 2000-11-30 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| GB9920548D0 (en) | 1999-08-31 | 1999-11-03 | Rhone Poulenc Rorer Sa | Treatment of hepatocellular carcinoma |
| ITMI20001107A1 (it) | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
| ITMI20020680A1 (it) | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento |
| ITMI20020681A1 (it) | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina |
| EP1585548B1 (en) | 2002-12-09 | 2018-06-27 | Abraxis BioScience, LLC | Compositions and methods of delivery of pharmacological agents |
| MXPA05006169A (es) | 2002-12-09 | 2006-03-30 | American Biosciences | Composiciones y metodos para el suministro de agentes farmacologicos. |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| ES2678448T3 (es) | 2005-02-18 | 2018-08-10 | Abraxis Bioscience, Llc | Combinaciones y modos de administración de agentes terapéuticos y terapia combinada |
| US20070166388A1 (en) * | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| TWI417114B (zh) * | 2005-08-31 | 2013-12-01 | Abraxis Bioscience Llc | 具有增強穩定性之弱水溶性藥物之組合物及其製備方法 |
| JP5368093B2 (ja) | 2005-08-31 | 2013-12-18 | アブラクシス バイオサイエンス， エルエルシー | 増大した安定性を有する難水溶性薬剤の組成物および調製の方法 |
| EP2338488A1 (en) * | 2006-05-26 | 2011-06-29 | Bayer HealthCare, LLC | Drug combinations with substituted diaryl ureas for the treatment of cancer |
| US20080280987A1 (en) | 2006-08-31 | 2008-11-13 | Desai Neil P | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| CA2662140A1 (en) | 2006-08-31 | 2008-03-06 | Abraxis Bioscience, Llc | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| CA2663878A1 (en) * | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Mir-200 regulated genes and pathways as targets for therapeutic intervention |
| CA2672618C (en) | 2006-12-14 | 2021-03-02 | Abraxis Bioscience, Llc | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| KR20090118999A (ko) | 2007-03-07 | 2009-11-18 | 아브락시스 바이오사이언스, 엘엘씨 | 항암제로서 라파마이신 및 알부민을 포함하는 나노입자 |
| JP5641927B2 (ja) * | 2007-04-13 | 2014-12-17 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | Ｓｐａｒｃ及びその使用方法 |
| EP3326630A3 (en) | 2007-05-03 | 2018-08-29 | Abraxis BioScience, LLC | Methods and compositions for treating pulmonary hypertension |
| DK2155188T3 (da) | 2007-06-01 | 2013-11-04 | Abraxis Bioscience Llc | Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft |
| CA2721153C (en) | 2008-04-10 | 2018-10-02 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
| JP2011517683A (ja) | 2008-04-10 | 2011-06-16 | アブラクシス バイオサイエンス， エルエルシー | 疎水性タキサン誘導体の組成物およびその使用 |
| BRPI0922823A2 (pt) | 2008-12-11 | 2015-08-18 | Abraxis Bioscience Llc | Combinações e modos de administração de agentes terapêuticos e terapia de combinação |
| AU2010224012B2 (en) | 2009-03-13 | 2016-04-28 | Abraxis Bioscience, Llc | Combination therapy with thiocolchicine derivatives |
| CA2758200A1 (en) | 2009-04-10 | 2010-10-14 | Abraxis Bioscience, Llc | Nanoparticle formulations and uses thereof |
| CN102460167B (zh) | 2009-04-15 | 2015-07-22 | 阿布拉科斯生物科学有限公司 | 不含朊病毒的纳米颗粒组合物和方法 |
| NZ598588A (en) | 2009-08-25 | 2014-05-30 | Abraxis Bioscience Llc | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors |
| ES2580135T3 (es) | 2010-03-26 | 2016-08-19 | Abraxis Bioscience, Llc | Métodos de tratamiento de carcinoma hepatocelular |
| NZ628423A (en) | 2010-03-29 | 2016-03-31 | Abraxis Bioscience Llc | Methods of treating cancer |
| AU2011232862B2 (en) | 2010-03-29 | 2016-03-03 | Abraxis Bioscience, Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
| MY188911A (en) | 2010-06-02 | 2022-01-13 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
| RU2576609C2 (ru) | 2010-06-04 | 2016-03-10 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечение рака поджелудочной железы |
| KR101850566B1 (ko) | 2010-06-07 | 2018-04-19 | 아브락시스 바이오사이언스, 엘엘씨 | 증식성 질환의 치료를 위한 조합 치료 방법 |
| CA3063641A1 (en) | 2011-04-28 | 2012-11-01 | Abraxis Bioscience, Llc | Intravascular delivery of nanoparticle compositions and uses thereof |
| DK2790675T3 (da) | 2011-12-14 | 2019-09-09 | Abraxis Bioscience Llc | Anvendelse af polymerexcipienser til frysetørring eller frysning af partikler |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US20140186447A1 (en) | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
| US20140199404A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on level of a nucleoside transporter |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| US20140199405A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
-
2011
- 2011-03-25 ES ES11760333.2T patent/ES2580135T3/es active Active
- 2011-03-25 HU HUE11760333A patent/HUE027749T2/en unknown
- 2011-03-25 US US13/583,603 patent/US9370494B2/en active Active
- 2011-03-25 EP EP14200645.1A patent/EP2898884B1/en active Active
- 2011-03-25 CA CA2793536A patent/CA2793536C/en active Active
- 2011-03-25 MX MX2016015444A patent/MX359413B/es unknown
- 2011-03-25 HR HRP20160609TT patent/HRP20160609T1/hr unknown
- 2011-03-25 KR KR1020127027815A patent/KR101786142B1/ko active Active
- 2011-03-25 MX MX2012010936A patent/MX346861B/es active IP Right Grant
- 2011-03-25 PL PL11760333.2T patent/PL2552438T3/pl unknown
- 2011-03-25 LT LTEP11760333.2T patent/LT2552438T/lt unknown
- 2011-03-25 ES ES14200645.1T patent/ES2675212T3/es active Active
- 2011-03-25 CN CN201180025949.1A patent/CN103052385B/zh active Active
- 2011-03-25 AU AU2011230512A patent/AU2011230512B2/en active Active
- 2011-03-25 NZ NZ602382A patent/NZ602382A/en unknown
- 2011-03-25 DK DK11760333.2T patent/DK2552438T3/en active
- 2011-03-25 CN CN201510242264.2A patent/CN104784121A/zh active Pending
- 2011-03-25 PT PT117603332T patent/PT2552438T/pt unknown
- 2011-03-25 WO PCT/US2011/030037 patent/WO2011119988A1/en not_active Ceased
- 2011-03-25 BR BR112012024349A patent/BR112012024349A2/pt not_active Application Discontinuation
- 2011-03-25 CA CA3051495A patent/CA3051495A1/en not_active Abandoned
- 2011-03-25 EP EP11760333.2A patent/EP2552438B1/en active Active
- 2011-03-25 JP JP2013501523A patent/JP5847156B2/ja active Active
- 2011-03-28 TW TW100110703A patent/TWI495467B/zh active
-
2012
- 2012-09-11 IL IL221886A patent/IL221886A/en active IP Right Grant
-
2013
- 2013-02-28 US US13/781,480 patent/US20140079787A1/en not_active Abandoned
-
2015
- 2015-04-28 JP JP2015091142A patent/JP2015134825A/ja active Pending
-
2016
- 2016-05-20 US US15/160,598 patent/US20160374952A1/en not_active Abandoned
- 2016-08-08 IL IL247171A patent/IL247171B/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2580135T3 (es) | Métodos de tratamiento de carcinoma hepatocelular | |
| AU2011261685B2 (en) | Methods of treatment of pancreatic cancer | |
| RU2561055C2 (ru) | Комбинированная терапия композициями наночастиц таксана и ингибиторами хэджхог | |
| AU2013203699B2 (en) | Methods of treating pancreatic cancer | |
| EP2968253A1 (en) | Methods of treatment of pediatric solid tumor | |
| HK1181665B (en) | Methods of treatment of hepatocellular carcinoma | |
| HK1212926B (en) | Methods of treatment of hepatocellular carcinoma |